alluvipeptides213919 - Profile

About me

Profile

Alluvi, formerly BI 4744, offers a promising breakthrough in obesity care. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates

https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/